Sanofi

🇫🇷France

Country: 🇫🇷France

Ownership: Public

Employees: 87.9K

Market Cap: $141.3B

Website: http://www.sanofi.com

Introduction: Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Clinical Trials

A Study to Evaluate the Pharmacokinetic Profiles of Single 14 mg Teriflunomide Tablet in Healthy Chinese Volunteers

Phase 1

Completed

Conditions: Multiple Sclerosis

Interventions: Drug: Teriflunomide HMR1726
Drug: cholestyramine

First Posted Date: 2014-01-28

Last Posted Date: 2014-08-21

Lead Sponsor: Sanofi

Target Recruit Count: 12

Registration Number: NCT02046629

Locations: 🇨🇳
Investigational Site Number 156001, Shanghai, China

A Phase 1 Study of an Investigational Drug, ALN-AT3SC, in Healthy Volunteers and Hemophilia A or B Patients

Phase 1

Completed

Conditions: Hemophilia B
Hemophilia A

Interventions: Drug: Sterile Normal Saline (0.9% NaCl)
Drug: ALN-AT3SC

First Posted Date: 2014-01-14

Last Posted Date: 2020-12-19

Lead Sponsor: Sanofi

Target Recruit Count: 51

Registration Number: NCT02035605

Locations: 🇬🇧
Clinical Trial Site, Truro, United Kingdom

Efficacy and Safety of Insulin Glargine in Patients With Type 2 Diabetes With Inadequate Control on DPP-4 Inhibitor Therapy

Phase 4

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: INSULIN GLARGINE
Drug: Metformin
Drug: DPP-4 inhibitor
Drug: Sulphonylurea

First Posted Date: 2014-01-06

Last Posted Date: 2015-08-27

Lead Sponsor: Sanofi

Target Recruit Count: 109

Registration Number: NCT02027753

Locations: 🇰🇷
Sanofi-Aventis Administrative Office, Seoul, Korea, Republic of

Phase III Study To Evaluate Alirocumab in Patients With Hypercholesterolemia Not Treated With a Statin (ODYSSEY CHOICE II)

Phase 3

Completed

Conditions: Hypercholesterolemia

Interventions: Drug: Alirocumab
Drug: Placebo (for Alirocumab)
Other: Diet Alone
Drug: Non-statin LMT

First Posted Date: 2013-12-30

Last Posted Date: 2018-07-27

Lead Sponsor: Sanofi

Target Recruit Count: 233

Registration Number: NCT02023879

Locations: 🇳🇿
Investigational Site Number 554701, Christchurch, New Zealand
🇪🇸
Investigational Site Number 724707, Barcelona, Spain
🇪🇸
Investigational Site Number 724705, Granada, Spain

and more 40 locations

Sarilumab Effect on the Pharmacokinetics of Simvastatin

Phase 1

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: sarilumab SAR153191 (REGN88)
Drug: simvastatin

First Posted Date: 2013-12-23

Last Posted Date: 2016-04-07

Lead Sponsor: Sanofi

Target Recruit Count: 19

Registration Number: NCT02017639

Locations: 🇺🇸
Investigational Site Number 840001, Dallas, Texas, United States
🇰🇷
Investigational Site Number 410002, Seoul, Korea, Republic of
🇺🇸
Investigational Site Number 840003, Jackson, Tennessee, United States

and more 2 locations

A Safety and Efficacy Study of SAR405838 and Pimasertib in Cancer Patients

Phase 1

Completed

Conditions: Neoplasm Malignant

Interventions: Drug: SAR405838
Drug: Pimasertib

First Posted Date: 2013-11-15

Last Posted Date: 2016-02-25

Lead Sponsor: Sanofi

Target Recruit Count: 26

Registration Number: NCT01985191

Locations: 🇳🇱
Investigational Site Number 528002, Utrecht, Netherlands
🇫🇷
Investigational Site Number 250001, Villejuif Cedex, France
🇳🇱
Investigational Site Number 528003, Rotterdam, Netherlands

and more 1 locations

Effect of Alirocumab on Lipid Metabolism in Adults With Elevated LDL-Cholesterol

Phase 1

Completed

Conditions: Hypercholesterolemia

Interventions: Drug: alirocumab
Drug: Placebo

First Posted Date: 2013-10-10

Last Posted Date: 2017-05-02

Lead Sponsor: Sanofi

Target Recruit Count: 20

Registration Number: NCT01959971

Locations: 🇺🇸
Investigational Site Number 840001, New York, New York, United States

Safety And Tolerability Of Lixisenatide In Monotherapy In Patients With Type 2 Diabetes

Phase 3

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: lixisenatide AVE0010

First Posted Date: 2013-10-10

Last Posted Date: 2015-04-09

Lead Sponsor: Sanofi

Target Recruit Count: 361

Registration Number: NCT01960179

Locations: 🇯🇵
Investigational Site Number 392009, Kisarazu-Shi, Japan
🇯🇵
Investigational Site Number 392001, Shinjuku-Ku, Japan
🇯🇵
Investigational Site Number 392015, Chuo-Ku, Japan

and more 27 locations

Study of Aflibercept as Maintenance Therapy Following Induction With Aflibercept in Combination With XELOX, as First-Line Treatment for Metastatic Colorectal Cancer Patient

Phase 1

Terminated

Conditions: Colorectal Cancer Metastatic

Interventions: Drug: Aflibercept AVE0005
Drug: Oxaliplatin
Drug: Capecitabine

First Posted Date: 2013-10-07

Last Posted Date: 2016-04-18

Lead Sponsor: Sanofi

Target Recruit Count: 4

Registration Number: NCT01955629

Locations: 🇮🇹
Investigational Site Number 380-001, Genova, Italy
🇮🇹
Investigational Site Number 380-002, Milano, Italy

Open Label Study of Long Term Safety Evaluation of Alirocumab

Phase 3

Completed

Conditions: Hypercholesterolemia

Interventions: Drug: Alirocumab
Drug: Lipid-Modifying Therapy (LMT)

First Posted Date: 2013-10-01

Last Posted Date: 2018-07-24

Lead Sponsor: Sanofi

Target Recruit Count: 986

Registration Number: NCT01954394

Locations: 🇺🇸
Investigational Site Number 840321, Huntsville, Alabama, United States
🇺🇸
Investigational Site Number 840334, Bell Gardens, California, United States
🇺🇸
Investigational Site Number 840319, Fountain Valley, California, United States

and more 174 locations

Home Terms & Conditions Privacy Policy